Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

The NEO-811-101 study is an open-label, first-in-human, Phase 1/2 dose escalation and expansion study testing NEO-811, an ARNT molecular glue degrader, in subjects with locally advanced or metastatic non-resectable clear cell renal cell carcinoma. The study will test NEO-811 initially as a monotherapy.

Trial Details

NCT ID
NCT07300241
Phase
PHASE1
Sponsor
Neomorph, Inc
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • NEO-811
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • San Diego, California, United States|32.71571,-117.16472
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Miami, Florida, United States|25.77427,-80.19366
  • Zion, Illinois, United States|42.44613,-87.83285

Key Eligibility Criteria

  • Subjects with locally advanced or metastatic non-resectable clear cell renal cell carcinoma (ccRCC).
  • Subjects must have progressed on or refused standard therapies.
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1.
  • Estimated life expectancy, in the judgment of the Investigator, of at least 12 weeks.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →